Searched for
ZAYNICH DRUG DCGI
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check detailsWockhardt's shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections....- Wockhardt shares jump 17%, hit fresh 52-week highWockhardt extended its winning streak for the third straight session, drawing strong investor interest with trading volumes surging over 4....
- Wockhardt eyes USD 7 billion market opportunity for antibiotic Zaynich in US, EuropeWockhardt's new antibiotic, Zaynich, targeting gram-negative infections, anticipates a significant USD 7 billion market in the US and Europ...
- Wockhardt Q2 Results: Net loss narrows to Rs 16 crore, revenue rises 7%Drugmaker Wockhardt on Wednesday reported a net loss of Rs 16 crore in Q2FY25 led by improved performance across UK, India and emerging mar...
Load More